Ipsen withdrew tazemetostat worldwide for follicular lymphoma and epithelioid sarcoma after new trial data suggested a less favorable safety profile than previously characterized. SYMPHONY-1 ...

Ipsen will withdraw Tazverik’s follicular lymphoma and epithelioid sarcoma indications as emerging data point to an elevated ...

Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all ...

Ipsen found cases of secondary malignancies in a confirmatory study of Tavzerik, a medicine it got in a purchase of Epizyme ...

Ipsen said it will now pull Tazverik from the market in all countries where it has rights to the first-in-class, chemotherapy ...

South University (SU) is proud to highlight a powerful example of its mission in action, as faculty from the SU Tampa ...

More than 400 cartons of Nilotinib capsules were voluntarily recalled by Cipla USA after failing manufacturing specifications ...

Based on the clinical trial findings, Ipsen is withdrawing Tazverik across all indications, including both follicular lymphoma and epithelioid sarcoma, and is discontinuing all active tazemetostat ...

Ipsen telegraphed plans to acquire Epizyme and the FDA-approved Tazverik in June 2022, two years after the med’s clearance in the U.S. as both an epithelioid sarcoma and follicular lymphoma treatment.

Confirmatory trial on tazemetostat suggested a link with secondary hematologic malignancie ...

Ipsen notified Hutchmed that it was "voluntarily" withdrawing the drug from US markets, prompting Hutchmed to recall Tazverik in China, Hong Kong and Macau. It is also discontinuing all active ...